180 related articles for article (PubMed ID: 6809898)
1. Effect of dopamine agonists and antagonists on DOPA formation in the substantia nigra.
Argiolas A; Melis MR; Fadda F; Serra G; Gessa GL
J Neurochem; 1982 Jan; 38(1):75-9. PubMed ID: 6809898
[TBL] [Abstract][Full Text] [Related]
2. Evidence for dopamine autoreceptors controlling dopamine synthesis in the substantia nigra.
Argiolas A; Melis MR; Fadda F; Gessa GL
Brain Res; 1982 Feb; 234(1):177-81. PubMed ID: 6800566
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of psychotropic drugs on dihydroxyphenylacetic acid (DOPAC) in the rat substantia nigra and caudate nucleus.
Fadda F; Argiolas A; Stefanini E; Gessa GL
Life Sci; 1977 Aug; 21(3):411-7. PubMed ID: 895373
[No Abstract] [Full Text] [Related]
4. 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
Elverfors A; Pileblad E; Lagerkvist S; Bergquist F; Jonason J; Nissbrandt H
J Neurochem; 1997 Oct; 69(4):1684-92. PubMed ID: 9326297
[TBL] [Abstract][Full Text] [Related]
5. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
Nissbrandt H; Engberg G; Pileblad E
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
[TBL] [Abstract][Full Text] [Related]
6. Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade.
Reches A; Wagner HR; Jackson-Lewis V; Fahn S
Brain Res; 1985 Nov; 347(2):346-9. PubMed ID: 3933764
[TBL] [Abstract][Full Text] [Related]
7. Increase of striatal dopamine turnover by drugs: interference with granular storage or receptor blackade?
Saner A; Pletscher A
Eur J Pharmacol; 1977 Mar; 42(2):155-60. PubMed ID: 844496
[TBL] [Abstract][Full Text] [Related]
8. Reserpine-insensitive dopamine release in the substantia nigra?
Elverfors A; Nissbrandt H
Brain Res; 1991 Aug; 557(1-2):5-12. PubMed ID: 1720998
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation.
Magnusson O; Mohringe B; Fowler CJ
J Neural Transm; 1987; 69(3-4):163-77. PubMed ID: 2957465
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
[TBL] [Abstract][Full Text] [Related]
11. NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.
Nissbrandt H; Engberg G; Wikström H; Magnusson T; Carlsson A
Naunyn Schmiedebergs Arch Pharmacol; 1988 Aug; 338(2):148-61. PubMed ID: 3141816
[TBL] [Abstract][Full Text] [Related]
12. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum.
Elverfors A; Nissbrandt H
Neuropharmacology; 1992 Jul; 31(7):661-70. PubMed ID: 1328918
[TBL] [Abstract][Full Text] [Related]
13. Evidence for dopamine release and metabolism beyond the control of nerve impulses and dopamine receptors in rat substantia nigra.
Nissbrandt H; Pileblad E; Carlsson A
J Pharm Pharmacol; 1985 Dec; 37(12):884-9. PubMed ID: 2868096
[TBL] [Abstract][Full Text] [Related]
14. Increase in D2 dopamine receptors in the substantia nigra after chronic (-)-sulpiride treatment.
Stefanini E; Frau M; Gessa GL
Brain Res; 1991 Aug; 555(2):340-2. PubMed ID: 1834311
[TBL] [Abstract][Full Text] [Related]
15. Turnover of dopamine and dopamine metabolites in rat brain: comparison between striatum and substantia nigra.
Nissbrandt H; Carlsson A
J Neurochem; 1987 Sep; 49(3):959-67. PubMed ID: 3612134
[TBL] [Abstract][Full Text] [Related]
16. N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors.
Argiolas A; Mereu G; Serra G; Melis MR; Fadda F; Gessa GL
Brain Res; 1982 Jan; 231(1):109-16. PubMed ID: 6799148
[TBL] [Abstract][Full Text] [Related]
17. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
Claustre Y; Fage D; Zivkovic B; Scatton B
J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
[TBL] [Abstract][Full Text] [Related]
18. Evidence for dopamine autoreceptors in mesocortical dopamine neurons.
Fadda F; Gessa GL; Marcou M; Mosca E; Rossetti Z
Brain Res; 1984 Feb; 293(1):67-72. PubMed ID: 6423212
[TBL] [Abstract][Full Text] [Related]
19. d-Amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities.
Demarest KT; Lawson-Wendling KL; Moore KE
Biochem Pharmacol; 1983 Feb; 32(4):691-7. PubMed ID: 6403019
[No Abstract] [Full Text] [Related]
20. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol.
Nowak JZ; Arbilla S; Galzin AM; Langer SZ
J Pharmacol Exp Ther; 1983 Aug; 226(2):558-64. PubMed ID: 6875865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
